Regenative Labs announces groundbreaking Wharton's Jelly research demonstrating HCT/P compliance after processing
Retrieved on:
Monday, August 15, 2022
FDA, Baylor College of Medicine, Multimedia, Association, American Association, Literature, Regenerative medicine, Intervertebral disc, Technology, Spine, American Association of Tissue Banks, 361, Hospital, Research, Spinal fusion, Pain, Department, Compliance, SEM, Institute, AATB, Patient, ECM, Health, Degenerative disc disease, Foot, Scanning electron microscope, Cartilage, Wake Forest Institute for Regenerative Medicine, IRB, Connective tissue, Physician, Knee, Ankle, Hip, Wharton, Shoulder, Labs, Public sector banks in India, DDD, Microscope, Pharmaceutical industry, Medical device, Ibuprofen, Pharmacology, Medicine
PENSACOLA, Fla., Aug. 15, 2022 /PRNewswire/ -- Regenative Labs, a leading HCT/P manufacturer, has co-authored a pioneering paper together with experts from The Institute of Regenative Medicine and the Department of Pharmacology and Chemical Biology, Baylor College of Medicine.
Key Points:
- Regenative Labs has pioneered the use of perinatal tissue allografts and is pleased that this paper supports our current homologous use practices, consistent with our 361 status.
- About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient's conditions using Wharton's Jelly innovations rather than masking the pain with other treatments.
- Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development.
- Regenative Labs's expert product research and development team compliesFDA guidelines of minimal manipulation for homologous use.